MarketPeel
Insider Trading Intelligence
AG

Ashoo Gupta

FDMT
VP, FINANCE AND CONTROLLER · 4D MOLECULAR THERAPEUTICS, INC. · CIK 0002091461
FILING MIX · LIFETIME33%/67%
BUYS
4
SELLS
8
TOTAL VALUE
$6.7K
COMPANIES
1
ACTIVE SINCE
Dec 2025
HOLDINGS NOW
47,135
AVG SELL PX
$8.64
TRADE KIND
SHOWING 12 / 12
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
4 backtested trades · 8 horizons · 10 pending
Forward-return performance of every backtestable P/S trade by Ashoo Gupta, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d4+50.00%+0.09%-0.40%+0.49%+0.49%
14d4+50.00%-2.78%+0.75%-3.53%-3.53%
30d4+50.00%+2.37%+4.42%-2.04%-2.04%
60d4+50.00%+1.63%+0.84%+4.81%+4.81%
90d4+50.00%+0.87%+4.77%-3.90%-3.90%
180d4(2 pending)+0.00%+1.73%+8.87%-7.14%-7.14%
1y4(4 pending)
2y4(4 pending)
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
FDMT · 47,135 shares · as of Mar 20, 2026
011,80623,61235,41847,2242026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2025
2026
FLOW · 4 buys / 8 sellsCOVERAGE · 2 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
FDMT
4D MOLECULAR THERAPEUTICS, INC.
SALE
VP, Finance and Controller
80$8.61$68947,055Mar 20, 2026Mar 24, 2026View →
FDMT
4D MOLECULAR THERAPEUTICS, INC.
PURCHASE
VP, Finance and Controller
86547,224Mar 20, 2026Mar 24, 2026View →
FDMT
4D MOLECULAR THERAPEUTICS, INC.
SALE
VP, Finance and Controller
310$8.61$2.7K46,914Mar 20, 2026Mar 24, 2026View →
FDMT
4D MOLECULAR THERAPEUTICS, INC.
SALE
VP, Finance and Controller
2213,087Mar 20, 2026Mar 24, 2026View →
FDMT
4D MOLECULAR THERAPEUTICS, INC.
SALE
VP, Finance and Controller
86512,119Mar 20, 2026Mar 24, 2026View →
FDMT
4D MOLECULAR THERAPEUTICS, INC.
PURCHASE
VP, Finance and Controller
22147,135Mar 20, 2026Mar 24, 2026View →
FDMT
4D MOLECULAR THERAPEUTICS, INC.
SALE
VP, Finance and Controller
79$8.68$68646,359Dec 20, 2025Dec 23, 2025View →
FDMT
4D MOLECULAR THERAPEUTICS, INC.
SALE
VP, Finance and Controller
2203,308Dec 20, 2025Dec 23, 2025View →
FDMT
4D MOLECULAR THERAPEUTICS, INC.
PURCHASE
VP, Finance and Controller
22046,438Dec 20, 2025Dec 23, 2025View →
FDMT
4D MOLECULAR THERAPEUTICS, INC.
SALE
VP, Finance and Controller
310$8.68$2.7K46,218Dec 20, 2025Dec 23, 2025View →
FDMT
4D MOLECULAR THERAPEUTICS, INC.
PURCHASE
VP, Finance and Controller
86646,528Dec 20, 2025Dec 23, 2025View →
FDMT
4D MOLECULAR THERAPEUTICS, INC.
SALE
VP, Finance and Controller
86612,984Dec 20, 2025Dec 23, 2025View →
Other insiders · FDMT
Loading peer insiders…
About this filer
CIK 0002091461
ROLE
VP, Finance and Controller
PRIMARY
FDMT
COMPANIES
1
ACTIVE SINCE
Dec 2025
MARKETPEEL · /INSIDER/0002091461DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback